Regulatory T cell surface marker

Regulatory T cells (Tregs) are a specialized subpopulation of T lymphocytes that play a vital role in maintaining immune tolerance and preventing autoimmune diseases by suppressing overactive immune responses. The target described as a "proprietary novel surface marker" refers to an undisclosed protein expressed on the exterior of Tregs, which is utilized by biotechnology companies to specifically identify, isolate, or modulate these cells. In the context of autoimmune therapy, such as those developed by companies like Sonoma Biotherapeutics or GentiBio, these markers allow for the production of highly pure Treg cell products or the targeted delivery of agonistic signals to dampen inflammation. Conversely, in immuno-oncology, these markers may be targeted by monoclonal antibodies to deplete Tregs within the tumor microenvironment, thereby removing a major barrier to anti-tumor immunity. The use of a proprietary marker is intended to provide superior specificity over traditional markers like CD25, which is also expressed on activated effector T cells, thus reducing off-target effects and improving therapeutic outcomes.

Other names

Treg surface markerNovel Treg surface antigenProprietary Treg selection markerUndisclosed Treg marker

Targeting of the surface marker to either deplete regulatory T cells (in oncology) or to isolate, activate, and expand them for cell therapy (in autoimmune diseases).